Clinical Trial: SAFETY OF A SECOND DOSE OF TENECTEPLASE IN SELECTED ACUTE ISCHEMIC STROKE PATIENTS NOT RESPONDING TO THE FIRST DOSE

U.S., Jan. 31 -- ClinicalTrials.gov registry received information related to the study (NCT06801054) titled 'SAFETY OF A SECOND DOSE OF TENECTEPLASE IN SELECTED ACUTE ISCHEMIC STROKE PATIENTS NOT RESPONDING TO THE FIRST DOSE' on Jan. 24.

Brief Summary: In this pilot safety study, we will give a second dose of Intravenous Tenecteplase (IV TNK) to patients receiving the initial TNK dose within 3 hrs of last known normal (LKN), have a baseline National Institutes of Health Stroke Scale (NIHSS) > 6, and who do not clinically improve within 45 minutes of the first dose, or who improve but then deteriorate, and can still be treated within 4.5 hours from LKN. Patients will require a second computed tomography (CT) scan to rule out any bleeding, a...